← All trials
NCT05991427
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 7, 2023
- Primary completion
- Sep 30, 2024
- Completion date
- Dec 31, 2024
- First posted
- Aug 14, 2023
- Last posted
- Nov 9, 2023
- Enrollment
- 65
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tianjin Cansino Biotechnology IncLead sponsor
- Canadian Center for VaccinologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.